• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    6/16/23 1:32:42 PM ET
    $CHRS
    $EVLO
    $MNK
    $NAVB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CHRS alert in real time by email

    Gainers

    • Oncorus (NASDAQ:ONCR) shares moved upwards by 144.6% to $0.19 during Friday's regular session. Trading volume for Oncorus's stock is 170.4 million as of 13:31 EST. This is 12952.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.9 million.
    • Evelo Biosciences (NASDAQ:EVLO) stock increased by 119.66% to $0.18. As of 13:31 EST, Evelo Biosciences's stock is trading at a volume of 122.3 million, which is 2749.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.3 million.
    • SCWorx (NASDAQ:WORX) stock moved upwards by 58.45% to $0.6. Trading volume for this security as of 13:31 EST is 59.9 million, which is 4062.0% of its average full-day volume over the last 100 days. The company's market cap stands at $7.7 million.
    • Navidea Biopharmaceutical (AMEX:NAVB) stock increased by 30.36% to $0.11. The current volume of 78.1 million shares is 3507.3% of Navidea Biopharmaceutical's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $3.7 million.
    • Sientra (NASDAQ:SIEN) shares moved upwards by 22.59% to $2.17. Trading volume for this security as of 13:31 EST is 629.5K, which is 67.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.2 million.
    • Mallinckrodt (AMEX:MNK) shares rose 21.9% to $1.06. Trading volume for this security as of 13:31 EST is 2.2 million, which is 151.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.9 million.

    Losers

    • Universe Pharmaceuticals (NASDAQ:UPC) shares decreased by 38.6% to $0.51 during Friday's regular session. As of 13:31 EST, this security is trading at a volume of 1.7 million shares, making up 3474.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.0 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) stock fell 32.79% to $0.62. Trading volume for this security as of 13:31 EST is 18.7 million, which is 544.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.1 million.
    • Coherus BioSciences (NASDAQ:CHRS) shares decreased by 23.29% to $4.13. As of 13:31 EST, Coherus BioSciences's stock is trading at a volume of 10.1 million, which is 478.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $389.0 million.
    • Stereotaxis (AMEX:STXS) stock fell 19.33% to $1.63. The current volume of 1.5 million shares is 574.5% of Stereotaxis's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $131.4 million.
    • Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15.48% to $7.67. As of 13:31 EST, Olema Pharmaceuticals's stock is trading at a volume of 327.0K, which is 141.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $312.8 million.
    • Vaccinex (NASDAQ:VCNX) stock decreased by 13.64% to $0.38. Vaccinex's stock is trading at a volume of 242.8K shares as of 13:31 EST. This is 169.7% of its average full-day volume over the last 100 days. The company's market cap stands at $24.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CHRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHRS
    $EVLO
    $MNK
    $NAVB

    CompanyDatePrice TargetRatingAnalyst
    Olema Pharmaceuticals Inc.
    $OLMA
    2/11/2026$48.00Buy
    Stifel
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Stereotaxis Inc.
    $STXS
    12/16/2025$4.00Mkt Outperform
    Citizens JMP
    Olema Pharmaceuticals Inc.
    $OLMA
    10/8/2025$20.00Buy
    Guggenheim
    Coherus Oncology Inc.
    $CHRS
    9/4/2025Hold → Buy
    Maxim Group
    Olema Pharmaceuticals Inc.
    $OLMA
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    Coherus Oncology Inc.
    $CHRS
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    More analyst ratings

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Mitchell Shawnte exercised 40,000 shares at a strike of $4.37, sold $945,750 worth of shares (39,767 units at $23.78) and sold $5,753 worth of Comon Stock (233 units at $24.69) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    3/5/26 8:00:07 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP of Finance and Controller Austin Sasha Lu was granted 11,700 shares, increasing direct ownership by 261% to 16,188 units (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    2/17/26 9:35:05 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Austin Sasha Lu claimed ownership of 4,488 shares (SEC Form 3)

    3 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    2/17/26 9:33:24 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Olema Pharmaceuticals with a new price target

    Stifel initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $48.00

    2/11/26 7:52:37 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Coherus BioSciences with a new price target

    Oppenheimer initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $10.00

    1/23/26 8:18:28 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Olema Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $40.00

    1/7/26 9:13:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    SEC Filings

    View All

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    3/10/26 12:27:57 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Coherus Oncology Inc.

    10-K - Coherus Oncology, Inc. (0001512762) (Filer)

    3/9/26 4:56:30 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Coherus Oncology, Inc. (0001512762) (Filer)

    3/9/26 4:40:39 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Isaac Paul J bought $66,600 worth of shares (30,000 units at $2.22), increasing direct ownership by 11% to 97,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    11/18/25 3:22:17 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/11/25 3:38:02 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

    4 - Stereotaxis, Inc. (0001289340) (Issuer)

    3/10/25 10:32:20 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

    – LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 million in year ending cash, cash equivalents and marketable securities – – Conference call today at 4:30 p.m. Eastern Standard Time – REDWOOD CITY, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. "We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars

    3/9/26 4:15:00 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stereotaxis Reports 2025 Full Year Financial Results

    ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, a

    3/9/26 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SCWorx Announces New SaaS and Data Management Customer Supporting a Prominent Southeastern Healthcare Provider's Workday Platform

    New York, NY, March 04, 2026 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:SCWX), a leading provider of data management, analytics, and interoperability solutions for healthcare organizations, today announced that it has signed a new SaaS and data management customer agreement with a prominent Southeastern healthcare provider in support of its implementation and ongoing optimization of its Workday platform. The health system's integrated delivery network (IDN) comprises over 700 beds across multiple acute care hospitals and outpatient facilities, serving communities throughout the region. Under the agreement, SCWorx will provide its cloud-based data management and governance solutions to suppo

    3/4/26 10:11:22 AM ET
    $SCWX
    $WORX
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $CHRS
    $EVLO
    $MNK
    $NAVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer

    ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At SpyGlass, he will lead the finance and accounting functions as the company advances the Bimatoprost Drug Pad-IOL System (BIM-IOL System) toward late-stage development and potential commercialization. "We are excited to welcome Jean to SpyGlass Pharma as we continue to advance our clin

    1/6/26 8:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Financials

    Live finance-specific insights

    View All

    Stereotaxis Reports 2025 Full Year Financial Results

    ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. "The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I'm proud of what our team has accomplished and excited for the year ahead," said David Fischel, Chairman and CEO. "The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, a

    3/9/26 4:01:00 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

    REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its full year and fourth quarter 2025 financial results will be released after market close on Monday, March 9, 2026. Starting at 4:30 p.m. Eastern Time on March 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, March 9, 2026, starting at 4:30 p.m. Eastern Standard Time To access the conference call, please pre-register

    3/2/26 9:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026

    ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2025 financial results conference callWhen:Monday, March 9, 2026, at 4:30 p.m. ET (1:30 p.m. PT)Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 646-30

    2/12/26 9:00:00 AM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CHRS
    $EVLO
    $MNK
    $NAVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care